Want to see ATNM full AI Analyst Report?
ATNM Stock Chart & Stats
$1.08
-$0.03(-3.48%)
At close: 4:00 PM EDT
$1.08
-$0.03(-3.48%)
Day’s Range― - ―
52-Week Range$0.74 - $1.74
Previous Close$0.86
Volume113.35K
Average Volume (3M)166.22K
Market Cap
$43.39M
Enterprise Value-$3.88M
Total Cash (Recent Filing)$36.47M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)3.8
Beta1.71
Next Earnings
Nov 23, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding31,441,437
10 Day Avg. Volume199,722
30 Day Avg. Volume166,219
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.09
Enterprise Value/Revenue-0.11
Enterprise Value/Gross Profit-0.11
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.18
Revenue Forecast (FY)$35.00M
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionATNM-400’s activity across multiple solid-tumor models broadens Actinium’s potential addressable market beyond hematologic malignancies. Evidence of monotherapy and combination activity supports several development paths, although clinical validation remains necessary.
Intellectual Property And CapacityBroader patent protection can strengthen Actimab-A’s commercial defensibility, while additional manufacturing capacity supports execution of company-sponsored and NCI-related studies. Together, these changes improve the platform’s ability to advance toward upcoming clinical milestones.
Balance SheetVery low leverage and a stronger equity base provide Actinium with a more solid solvency position than many biotechnology peers. This reduces near-term balance-sheet pressure and preserves greater flexibility to fund development, despite continued reliance on external capital.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not currently self-funding. If this pattern persists, Actinium may need additional financing to sustain trials and operations, creating dilution or funding pressure over the next several quarters.
Weak Profitability QualityThe latest net income improvement is not supported by robust gross profitability, making earnings quality difficult to assess. Extremely thin margins and a history of large operating losses suggest that recent profitability may not yet represent a durable economic model.
Listing Compliance RiskThe compliance extension preserves the listing for now, but unresolved NYSE American requirements remain a structural corporate risk. Failure to demonstrate sufficient progress could threaten continued listing, potentially reducing market access and complicating future financing.
Actinium Pharmaceuticals News
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $0.73 and its highest was $1.74 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Actinium Pharmaceuticals’s market cap is $43.39M.
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Nov 23, 2026 which is in 32 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.003.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate is -0.24.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 31,441,437 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Currently, no hedge funds are holding shares in ATNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinium Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (224.07% Upside)
$3.50 (224.07% Upside)
Hedge Fund Trend
Decreased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 29.4%
Last 30 Days ▲ 19.4%
Last 30 Days ▲ 19.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.60%
12-Months-Change
Fundamentals
Return on Equity
83.42%
Trailing 12-Months
Asset Growth
-36.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
ATNM Stock 12 Month Forecast
Average Price Target
$3.50
▲(224.07% Upside)
Technical Analysis
Cellectar Biosciences
―
PDS Biotechnology
―
GT Biopharma
―
Marker Therapeutics
―
Celularity
―
Ownership Overview
7.10% Insiders
5.48% Mutual Funds
0.06% Other Institutional Investors
82.99% Public Companies and
Individual Investors